Viking Therapeutics - Viking is developing VK2735, a therapy for obesity, with phase 3 trials for the injectable formulation and phase 2 trials for the oral formulation soon to begin [3] - The anti-obesity medicine market is projected to reach 105billionannuallyby2030,withVikingaimingtocaptureashareofthisgrowingmarket[5]−Vikinghas942 million in cash, equivalents, and short-term investments as of Q2, with operating expenses of just over 34million,ensuringsufficientfundingforlate−stagetrials[6]−IfVK2735isapproved,Vikingcouldseesignificantreturns,especiallyifitcaptureseven1026 billion annually by 2032, up from 11.5billioncurrently,withSummitaimingtocarveoutanichewithivonescimab[9]−Summithas326 million in cash, equivalents, and short-term investments as of Q2, and recently raised 235million,providingamplecapitaltobringitsadvancedprogramstomarket[10]−Summit′sfirsttwoprogramscouldhitthemarketwithinthenext3−4years,withonereceivingFDAFastTrackdesignation[10]MarketComparison−Vikingistargetingthelargeranti−obesitymarket(105 billion by 2030), while Summit is focused on the smaller NSCLC market ($26 billion by 2032) [5][9] - Viking's internal R&D allows for further development of its candidates, while Summit relies on Akesobio's pipeline for future opportunities [12][13] - Viking is seen as a more appealing investment due to the larger market potential, despite being riskier without a collaborator like Akesobio [11][12]
Summit Therapeutics (SMMT) The Motley Fool·2024-10-13 16:11